NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.Edward M. Schaeffer, Deborah A. Freedman-Cass, Joshua M. Lang et al.|PubMed|2022Cited by 172
Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 ConsortiumMieke Van Hemelrijck, Michael Fahey, Ji Xi et al.|European Urology|2018Cited by 93
Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance InitiativeArveen Kalapara, Artitaya Lophatananon, Jan Verbeek et al.|European Urology Oncology|2019Cited by 37
Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) ConsortiumByung Ha Chung, Weiyu Li, Daan Nieboer et al.|European Urology Open Science|2022Cited by 27
Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance CohortsFrank‐Jan H. Drost, Nicole Benfante, Daan Nieboer et al.|European Urology|2019Cited by 24